GlassScriptPhysician profile
Brendan Lindgren
NPI 1508329459
$104,953.88
in general payments reported to CMS, 2019-2025
30 companies · $13K in 2025
The $13K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $90K · 2024: $1,729 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $90K · Consulting Fee: $7,948 · Food and Beverage: $5,904 · Travel and Lodging: $1,001 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $90,000.00 |
| Consulting Fee | $7,948.00 |
| Food and Beverage | $5,903.80 |
| Travel and Lodging | $1,001.08 |
| Education | $101.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $91,205.39 | 2023-2025 | Tysabri, Vumerity |
| Genentech USA, INC. | $8,583.37 | 2025 | Ocrevus, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $1,204.73 | 2024-2025 | |
| Pfizer INC. | $782.04 | 2024-2025 | |
| Abbvie INC. | $703.12 | 2024-2025 | |
| Emd Serono, INC. | $639.31 | 2023-2025 | Mavenclad, Mavenclad |
| Alexion Pharmaceuticals, INC. | $402.39 | 2024-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $218.02 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $146.61 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Vanda Pharmaceuticals INC. | $134.71 | 2024-2025 | Ponvory |
| Amgen INC. | $115.36 | 2024-2025 | Uplizna |
| Genzyme Corporation | $109.73 | 2025 | |
| Sk Life Science, INC. | $93.15 | 2024-2025 | Xcopri |
| Neurocrine Biosciences, INC. | $77.54 | 2025 | |
| Lundbeck LLC | $59.93 | 2024-2025 | Vyepti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $53.54 | 2025 | Vyvgart Hytrulo |
| Harmony Biosciences LLC | $49.53 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $39.04 | 2025 | Purified Cortrophin Gel |
| Acadia Pharmaceuticals INC | $37.33 | 2025 | Nuplazid |
| Neurelis, INC. | $34.54 | 2025 | Valtoco |
| Ucb, INC. | $33.98 | 2025 | Rystiggo |
| Tanabe Pharma America, INC. | $33.10 | 2025 | Radicava |
| Avadel Cns Pharmaceuticals, LLC | $32.51 | 2025 | Lumryz |
| Catalyst Pharmaceuticals, INC. | $31.25 | 2025 | |
| Jazz Pharmaceuticals INC. | $25.38 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $25.12 | 2025 | Dysport |
| Eisai INC. | $24.26 | 2024 | |
| Mallinckrodt Hospital Products INC. | $20.53 | 2025 | Acthar |
| Averitas Pharma INC. | $19.42 | 2025 | Qutenza |
| Axsome Therapeutics, INC. | $18.95 | 2025 | Symbravo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brendan Lindgren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.